Comparing adaptive SBRT to standard image-guided SBRT for localized prostate cancer
Official title: Is Adaptive SBRT for Prostate vs Image-guided Radiotherapy a True Evolution (ASPIRE)
Run by University Health Network, Toronto · NCT06825091 · Data updated 2026-11-12
This study is testing if a new type of targeted radiation therapy for prostate cancer can improve urinary health compared to the standard radiation treatment.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 320 (estimated) |
| Sponsor | University Health Network, Toronto Academic / other |
| Locations | 1 site (Toronto, Ontario) |
| Status | Recruiting |
| Started | February 4, 2025 |
| Main results expected | February 4, 2030 |
| Study ends | February 4, 2030 |
| Registry record updated | June 2, 2026 |
| Trial ID | NCT06825091 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include men over 18 years old diagnosed with localized prostate adenocarcinoma who are eligible for SBRT.
✕Probably not a fit
Patients who are planned for elective nodal irradiation or have contraindications to radiotherapy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The ASPIRE study is a Phase III randomized trial that investigates the effectiveness of adaptive stereotactic body radiotherapy (SBRT) compared to standard image-guided SBRT in patients with localized prostate cancer. This single-center study will enroll 320 participants and aims to determine if adaptive SBRT can enhance urinary outcomes while ensuring effective cancer control. Patients will be randomized into two groups, receiving either adaptive SBRT or standard SBRT, with stratification based on various clinical factors. The study will adhere to established dosing protocols for both treatment arms.
Why it matters
Potential benefit: If successful, this study could lead to improved urinary outcomes for patients undergoing treatment for localized prostate cancer.
How similar studies have gone: Other studies have shown promising results with adaptive radiotherapy approaches, suggesting potential benefits in similar contexts.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age \>18 years 2. Histologic diagnosis of prostate adenocarcinoma 3. Localized prostate cancer 4. Low risk, intermediate risk, or high risk allowed 5. Patient planned for prostate SBRT Exclusion Criteria: 1. Planned for elective nodal irradiation 2. Contraindications to radiotherapy 3. Patients with bilateral hip replacements, as they are ineligible for adaptive treatments at present time (either MR-guided or CT-guided)
Where it's running
-
Princess Margaret Cancer Center
Toronto, Ontario, Canada Recruiting
Study contacts
- Study coordinator: Rachel Glicksman, MD
- Email: rachel.glicksman@uhn.ca
- Phone: 416-946-4559
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Intraoperative Hyperspectral Imaging to guide prostate cancer removal
This study tests a hyperspectral imaging device during prostate surgery to see if it can help identify cancer at the edges of the removed tissue in men with localized prostate cancer.
-
Focal Micro-boost Radiotherapy for Localized Prostate Cancer
This study tests whether adding a small, targeted boost to MRI-visible prostate lesions during moderately hypofractionated radiotherapy can improve cancer control in men with localized intermediate- to high-risk prostate cancer.
-
Sonablate HIFU Registry for Prostate Cancer and BPH
This registry collects real-world data from men treated with Sonablate HIFU to see how well it works and how it affects urinary and sexual function over the long term.
-
Water IV: See if Aquablation helps localized prostate cancer patients choose active surveillance
This trial tests whether Aquablation therapy can be as safe and effective as choosing active surveillance for men with localized prostate cancer who are considering surveillance instead of immediate treatment.
-
Whole-gland prostate dose boost versus SBRT alone for PSMA-staged localized and locally advanced prostate cancer
We will test whether adding a whole-gland radiation boost (with brachytherapy or a stereotactic boost) improves cancer control compared with SBRT alone in men whose prostate cancer is confined to the prostate on PSMA PET.
-
Functional Lung-Sparing Planning Guided by Lung Perfusion PET/CT vs. Anatomy for Lung SBRT
We test whether planning lung SBRT with functional lung information from a PET/CT scan can spare healthy lung tissue and reduce side effects for adult patients with primary or metastatic lung tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.